Tous Actualités
Suivre
Abonner Amgen Inc.

Amgen Inc.

Final Results of a Phase 3 European Study Demonstrate Aranesp(R) Dosed Once Every Three Weeks is at Least as Effective as Weekly Dosing in Treating Patients With Chemotherapy-Induced Anaemia

Stockholm, Sweden (ots/PRNewswire)

Amgen Inc., (NASDAQ: AMGN)
the world's largest biotechnology company, announced that new data
from a randomised, double-blind Phase 3 study demonstrate that
Aranesp(r) (darbepoetin alfa) administered as a fixed dose of 500 mcg
once every three weeks is at least as effective as 2.25 mcg/kg of
darbepoetin alfa administered once weekly with respect to the need
for red blood cell transfusions in cancer patients with
chemotherapy-induced Anaemia and is effective in increasing
haemoglobin to Evidence Based Practice Guidelines target levels[1].
The results were presented at the 10th Congress of the European
Hematology Association. [Abstract #471]
In 2004, darbepoetin alfa was approved by the European Committee
for Medicinal Products for Human Use (CHMP) for every-three-week
dosing in patients with chemotherapy-induced Anaemia.
"Anaemia is one of the most common side effects of chemotherapy.
However, it is often under-treated, despite the availability of
treatments that have  been available for more than a decade," said
Jean-Luc Canon, MD, Centre  Notre Dame et Reine Fabiola, Charleroi,
Belgium. "The every three-week dosing schedule of Aranesp is
consistent with most chemotherapy regimens and may  allow physicians
to effectively treat Anaemia while reducing the time spent  by
patients, physicians and caregivers for Anaemia management."
In this study, patients with chemotherapy-induced Anaemia from 110
centres in Europe were randomised to receive either a fixed dose of
500 mcg of darbepoetin alfa every three weeks or 2.25 mcg/kg of
darbepoetin alfa once a week. Of the 672 patients assessed from week
five through the end of  the treatment period, the difference between
treatment groups was 6.8 percent with respect to the need for red
blood cell transfusion (23 percent of  patients receiving darbepoetin
alfa once every three weeks compared to 30  percent who received once
weekly dosing). Additionally, from week five  through the end of the
treatment period, 82 percent of patients receiving  darbepoetin alfa
every three weeks compared to 70 percent of patient  receiving
darbepoetin alfa once a week achieved the target haemoglobin  range
(11 to 13 g/dL) consistent with the current evidence based practice
guidelines issued by the European Organisation for Research and
Treatment of Cancer, American Society of Clinical Oncology, American
Society of Hematology and the National Comprehensive Cancer Network.
There were no differences in the safety profile between the two
treatment groups. The most frequently reported adverse events were
nausea, vomiting, fatigue and pyrexia.
About Aranesp
Aranesp is a recombinant erythropoietic protein (a protein that
stimulates production of oxygen-carrying red blood cells). Amgen
revolutionized Anaemia treatment with the development of recombinant
erythropoietin, Epoetin alfa. Building on this heritage, Amgen
developed Aranesp, a unique erythropoiesis stimulating protein, which
contains two additional sialic acid-containing carbohydrate chains
than the Epoetin alfa molecule and remains in the bloodstream longer
than Epoetin alfa because it has a longer half-life. By virtue of its
longer half-life, Aranesp should be administered less frequently than
Epoetin alfa in patients with chronic kidney disease (CKD).
Darbepoetin alfa was initially granted marketing authorization by
the European Commission in 2001 for the treatment of Anaemia
associated with chronic renal failure in adults and paediatric
subjects 11 years of age or older. In 2002, the European Commission
approved darbepoetin alfa for the treatment of Anaemia in adult
cancer patients receiving chemotherapy with solid tumours. This
patient population was subsequently expanded in 2003 to include all
adult cancer patients with non-myeloid malignancies receiving
chemotherapy.
Important Safety Information
Aranesp is contraindicated in patients with uncontrolled
hypertension. Erythropoietic therapies may increase the risk of
thrombotic and other serious events; regional guidelines should be
referred to for target and maximum haemoglobin levels, and dose
adjustment rules should be performed in line with regional
prescribing information. In a study with another erythropoietic
product, where the target Hb was 12-14 g/dL, an increased incidence
of thrombotic events, disease progression and mortality was seen.
Pure red cell aplasia (PRCA) has been observed in patients treated
with recombinant erythropoietic proteins. This has been reported
predominantly in patients with chronic renal failure. Aranesp should
be  discontinued in any patient with evidence of PRCA and the patient
evaluated for the presence of antibodies to erythropoietin products.
The most commonly reported side effects in clinical trials were
fatigue, edema, nausea,  vomiting, diarrhoea, fever and dyspnea.
About Amgen
Amgen is a global biotechnology company that discovers, develops,
manufactures and markets important human therapeutics based on
advances in cellular and molecular biology.
www.amgen.com
Forward-Looking Statement
This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below
and others that can be found in Amgen's Form 10-K for the year ended
December 31, 2004, and in Amgen's periodic reports on Form 10-Q and
Form 8-K. Amgen is providing this information as of the date of this
news release and does not undertake any obligation to update any
forward-looking statements contained in this document as a result of
new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results
may differ materially from those we project. Discovery or
identification of new product candidates or development of new
indications for existing products cannot be guaranteed and movement
from concept to product is uncertain; consequently, there can be no
guarantee that any particular product candidate or development of a
new indication for an existing product will be successful and become
a commercial product. Further, pre-clinical results do not guarantee
safe and effective performance of product candidates in humans. The
complexity of the human body cannot be perfectly, or sometimes, even
adequately modelled by computer or cell culture systems or animal
models. The length of time that it takes for us to complete clinical
trials and obtain regulatory approval for product marketing has in
the past varied and we expect similar variability in the future. We
develop product candidates internally and through licensing
collaborations, partnerships and joint ventures. Product candidates
that are derived from relationships may be subject to disputes
between the parties or may prove to be not as effective or as safe as
we may have believed at the time of entering into such relationship.
Also, we or others could identify side effects or manufacturing
problems with our products after they are on the market. In addition,
sales of our products are affected by the availability of
reimbursement and the reimbursement policies imposed by third party
payors, including governments, private insurance plans and managed
care providers, and may be affected by domestic and international
trends toward managed care and healthcare cost containment as well as
possible U.S. legislation affecting pharmaceutical pricing and
reimbursement. Government regulations and reimbursement policies may
affect the development, usage and pricing of our products.
In addition, we compete with other companies with respect to some
of our marketed products as well as for the discovery and development
of new products. We believe that some of our newer products, product
candidates or new indications for existing products, may face
competition when and as they are approved and marketed. Our products
may compete against products that have lower prices, established
reimbursement, superior performance, are easier to administer, or
that are otherwise competitive with our products. In addition, while
we routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors and there
can be no guarantee of our ability to obtain or maintain patent
protection for our products or product candidates. We cannot
guarantee that we will be able to produce commercially successful
products or maintain the commercial success of our existing products.
Our stock price may be affected by actual or perceived market
opportunity, competitive position, and success or failure of our
products or product candidates. Further, the discovery of significant
problems with a product similar to one of our products that implicate
an entire class of products could have a material adverse effect on
sales of the affected products and on our business and results of
operations.
Reference:
[1] Evidence based Practice Guidelines target level is 11 to 13
g/dL according to the European Organisation for Research and
Treatment of Cancer, the National Comprehensive Cancer Network and
the American Society of Clinical Oncology.

Contact:

Contact: Amgen Europe: Sabeena Ahmad, Phone: +41-41-369-2530 or
Porter Novelli: Inge Boets, Phone: +32-2-413-03-40